April 3, 2017 / 1:30 PM / 5 months ago

BRIEF-Jazz Pharma says completes rolling submission of NDA for Vyxeos (CPX-351)

April 3 (Reuters) - Jazz Pharmaceuticals Plc

* Jazz pharmaceuticals completes rolling submission of new drug application for vyxeos™ (cpx-351), an investigational treatment for acute myeloid leukemia

* Jazz pharmaceuticals plc - has requested a priority review for vyxeos nda, which, if granted, would accelerate expected timing of fda's review Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below